Data + Perspectives: Clinical Investigators Explore the Current and Future Management of ER-Positive Breast Cancer — A Special Audio Supplement


Interview with Harold J Burstein, MD, PhD

Topic 1: Use of genomic classifiers to inform therapeutic decision-making for ER-positive localized breast cancer
Topic 2: Prognostic and/or predictive utility of the various genomic assays for patients with node-negative and node-positive early breast cancer
Topic 3: Implications of the TAILORx intermediate-risk cohort results for adjuvant treatment for pre- and postmenopausal patients with localized breast cancer
Topic 4: Effects of prolonging adjuvant aromatase inhibitor therapy beyond 5 years on recurrence and cause-specific mortality
Topic 5: NSABP-B-42: Ten-year results of extended adjuvant endocrine therapy with letrozole for postmenopausal women with ER-positive breast cancer who have completed previous adjuvant therapy with an aromatase inhibitor (AI)
Topic 6: Optimizing the use of CDK4/6 inhibitors in the management of ER-positive metastatic breast cancer (mBC); overall survival findings and mechanisms of resistance
Topic 7: Management of de novo ER-positive, HER2-negative mBC
Topic 8: Choice of endocrine therapy partner for patients with de novo ER-positive, HER2-negative mBC
Topic 9: Approach for patients with mBC and disease progression on an AI
Topic 10: Selection and sequencing of CDK4/6 inhibitors in mBC; comparison of side-effect profiles
Topic 11: Incidence, identification and prognostic significance of PI3K mutations in patients with ER-positive mBC
Topic 12: Results of the Phase III SOLAR-1 trial evaluating alpelisib/fulvestrant versus fulvestrant alone for patients with ER-positive, HER2-negative advanced BC with or without a PIK3CA mutation after disease progression on first-line endocrine therapy; FDA approval for breast cancer with a PIK3CA mutation and current clinical role
Topic 13: Spectrum, frequency and severity of toxicities observed with alpelisib
Topic 14: Clinical experience with everolimus in mBC; potential for its use after disease progression on a CDK4/6 inhibitor
Topic 15: Biologic rationale for evaluation of the Bcl-2 inhibitor venetoclax in ER-positive mBC
Topic 16: Overview of the novel HER2-directed agents trastuzumab deruxtecan and tucatinib for HER2-positive mBC
Topic 17: Dual targeted approach for patients with ER/PR-positive, HER2-positive mBC
Topic 18: Investigation of other strategies designed to exploit the PI3K/AKT/mTOR pathway
Topic 19: Early activity and safety data with the use of CDK4/6 inhibitors as neoadjuvant therapy; ongoing evaluation and potential clinical role
Topic 20: Perspectives of Dr Burstein and Dr Love on the passing and legacy of the breast cancer revolutionary Dr Bernard Fisher
Topic 21: Advances in the adjuvant treatment of HER2-positive and triple-negative breast cancer
Harold J Burstein, MD, PhD
Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts
Neil Love, MD
Research To Practice
Miami, Florida